Biomarkers of ageing: what can your body reveal about your future health?

Chronological age is no longer the sole indicator of our health. Advanced analysis of vascular, metabolic, and epigenetic biomarkers allows us to evaluate the body’s true rate of ageing, turning clinical data into a personalised medical strategy to preserve long-term vitality.

Short answer

What are biomarkers of ageing? 

Biomarkers of ageing are measurable biological characteristics that help researchers assess how the body changes with age, beyond the number of years a person has lived. They can include patterns in DNA methylation, levels of certain proteins in the blood and measures of physical function. Studied individually or combined, they may help estimate aspects of biological age and identify patterns associated with future health. No single biomarker provides a complete picture of ageing, and many are still being evaluated for use in clinical care.

Biomarkers and their role in medicine

A biomarker is a measurable characteristic that provides information about a biological process, a disease or the body’s response to treatment. Biomarkers are already part of everyday medicine: blood glucose can help diagnose diabetes, while blood pressure measurements help identify hypertension. Depending on their purpose, they can support diagnosis, assess risk, monitor a condition or help guide treatment choices.

Their significance depends on the question being asked and the person being assessed. A clinician interprets results alongside medical history, symptoms, medicines and other relevant findings. Repeated measurements may also help reveal changes over time and inform whether care needs adjusting. In ageing research, scientists investigate whether individual biomarkers or combinations of measurements can describe aspects of biological ageing. A marker that is useful for diagnosing or monitoring a particular disease is not automatically a validated measure of biological age.

“Here is an example of how an individual with a normal weight and optimal blood pressure, yet presenting altered cardiovascular biomarkers—such as abnormal lipid profiles, hepatic steatosis, and increased liver stiffness—may be experiencing accelerated vascular ageing. This underlines the immediate priority of interventions aimed at controlling the factors that compromise these parameters.“

– Dr. Carlos Gutiérrez, ZEM Clinic Director

From scientific discovery to clinical relevance

Biomarkers of ageing are identified by studying measurable changes in the body and testing how they relate to age, physical function or future health outcomes. Researchers may analyse blood samples, DNA patterns or other biological measurements, often following participants over time. A promising finding must then be tested in independent groups to establish whether it holds beyond the people in whom it was first discovered.

Validation involves checking whether a measurement is reliable, whether it reflects the process or outcome being studied and whether it adds useful information beyond established measures. Researchers also need to understand how results vary across populations and testing conditions. For clinical use, a further question matters: does using the result help guide care in a way that benefits the patient? A biomarker that changes after an intervention may be scientifically interesting, but that change alone does not prove that someone will live longer or remain healthier.

How does the Horvath clock estimate biological age?

The Horvath clock is a scientific tool that estimates age by analysing chemical marks on DNA, known as DNA methylation. These marks help regulate gene activity without changing the underlying DNA sequence, and some follow patterns associated with age. Developed by researcher Steve Horvath in 2013, the original clock measures methylation at 353 specific sites and combines the results in a mathematical model to calculate an estimated age, called DNA methylation age or epigenetic age.

The model was trained using samples from people of different ages and multiple tissue types. Its estimate can be compared with chronological age to explore whether a sample’s methylation pattern appears older or younger than expected. Although widely discussed as a measure of biological age, the original clock was designed to predict chronological age. A higher or lower result does not, by itself, establish how healthy someone is or how long they will live.

“Today, we have many other types of epigenetic clocks, both second, and third generation, that measure not only general epigenetic age, but can also assess organ-specific ageing or the rate of biological ageing acceleration. Furthermore, there are biological age clocks that determine this through alternative approaches, such as transcriptomics and proteomics.”

– Dr. Carlos Gutiérrez

How accurate are biological age tests?

Biological age tests vary in accuracy, and no single method is established as the most accurate for every purpose. Some are designed to estimate chronological age, while others focus on predicting health risks or measuring the pace of ageing. Performing well at one task does not guarantee equal performance at another. Because biological age has no universally accepted reference standard, the most useful question is what a particular test has been shown to measure reliably.

For an individual, this means looking beyond the number on the report. Results can differ according to the method, sample type and laboratory procedures, and small changes between tests may reflect measurement variation rather than a meaningful biological change. For example, a lower age estimate on a repeat test does not automatically demonstrate that ageing has reversed. A useful assessment considers whether the test has been validated in people with similar characteristics, whether results are reproducible and whether they add information that can guide care.

Can biomarkers of ageing predict healthspan and lifespan?

Some biomarkers of ageing can help estimate the likelihood of future illness or death, but they cannot tell an individual exactly how long they will live or remain healthy. Studies that follow people over time have found that certain biological age measures provide information about these risks beyond chronological age alone. For example, the epigenetic clock GrimAge has shown associations with mortality and the development of conditions such as coronary heart disease. These findings support its use in research into ageing and long-term health.

Predicting healthspan involves several different outcomes. Developing a disease, losing physical independence and experiencing cognitive decline are distinct events, and one biomarker may not predict them equally well. A meaningful prediction therefore needs to specify the outcome, the timeframe and the population studied. For an individual, the potential value lies in adding context to preventive care and identifying priorities for further assessment.

Can biomarkers help predict the progression of cancer or Alzheimer’s disease?

Certain disease-specific biomarkers can help estimate how cancer or Alzheimer’s disease may progress, but they serve a different purpose from general biological age tests. In cancer care, some tumour markers provide information about how aggressive a cancer may be or its likelihood of returning. Others help identify suitable treatments or monitor whether treatment is working. Their relevance depends on the type and stage of cancer and the particular marker being measured. Results are interpreted alongside examinations, imaging and other clinical findings to inform an individual assessment.

In Alzheimer’s disease, biomarkers related to beta-amyloid, light neurofilament, the proteins involved in its characteristic brain changes, can help identify the underlying disease process. Certain combinations also help specialists estimate the likelihood and pace of future cognitive decline. However, detecting these changes does not establish exactly when symptoms will appear or how quickly they will develop. Interpretation requires a specialist assessment that considers memory and thinking skills, symptoms and medical history. A general biological age test alone cannot provide a reliable prognosis for either disease.

Advances in biomarkers for personalised medicine

Advances in biomarker research are helping scientists understand why people of the same age can have different health risks and care needs. One promising area is proteomics: the study of large numbers of proteins, including those circulating in the blood. Researchers are combining these measurements with machine learning to identify patterns associated with ageing in different organs. A study published in Nature Aging, for example, developed protein-based ageing clocks using UK Biobank data and tested them in populations in China and the United States. These measures provided information about future disease and mortality risk beyond established clinical and genetic risk factors.

For personalised medicine, the potential is to use this information to identify who might benefit from closer monitoring or a particular intervention. Biomarker-guided treatment is already established in some areas, including the selection of certain cancer therapies. Applying newer ageing biomarkers to routine preventive care requires further evidence that decisions based on their results improve health outcomes. The aim is to connect a person’s biological profile with care that has a clear, demonstrated benefit for them.

Understanding your biomarkers with ZEM

Understanding your biomarkers begins with understanding you. ZEM’s approach brings together clinically relevant biomarkers and health assessments, interpreted alongside your medical history, daily habits and personal priorities. The medical team helps you understand what the findings mean, which areas deserve attention and what may need further assessment.

“At ZEM, doctors help interpret biomarkers through a 360º approach, considering all dimensions of health and wellness, and establishing clear priorities. They design a realistic and sustainable intervention plan, tailored to each individual’s circumstances.“

– Dr. Carlos Gutiérrez 

For those seeking a broad, in-depth preventive assessment, ZEM’s Signature Health Check-Up offers a comprehensive understanding of current health, key risk factors and the lifestyle patterns that may influence long-term wellbeing. The medical team translates the findings into a personalised action plan, explaining what is working well, what deserves attention and which next steps are appropriate.

For a more extensive focus on ageing and long-term capacity, ZEM Prime Longevity is our most comprehensive longevity programme. It brings together blood tests, body scans, cognitive performance assessments and bone densitometry to explore complementary aspects of health and function. Interpreted together, these findings help inform a personalised strategy for preserving long-term health, vitality and independence.

Sources and references:

WhatsApp